SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing massive trading volume and a significant surge as investors react to a de-risking FDA update for its ANKTIVA bladder cancer application, which importantly does not require new clinical trials. This news, coupled with recent international approvals and high short interest, has ignited widespread community discussion about a potential short and gamma squeeze. The intense momentum highlights a fervent belief in the drug's long-term potential as a cancer treatment, driving bullish sentiment against a backdrop of active short positions.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is currently trending due to its recent award of a prime contract position on the U.S. Missile Defense Agency's SHIELD program, significantly bolstering its standing in government AI data training. The community is highly bullish on this development, anticipating a major breakout, potential short squeeze, and further expansion into defense and sovereign AI markets, with many viewing the company as undervalued.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to compelling positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, showcasing strong efficacy in treatment-resistant patients and a favorable safety profile. The community is buzzing about its "best-in-class" potential in a massive market and a possible short squeeze, with many anticipating significant upside or a partnership. Despite the early stage of development, the innovative mechanism is driving substantial investor conversation.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a significant licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as crucial validation for its non-mRNA technology. This development is intensifying community discussions about the stock's high short interest and potential for a squeeze, alongside ongoing pressure from an activist investor for management to expedite further partnerships and unlock core asset value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is capturing significant attention following multiple analyst upgrades and reports of a substantial U.S. defense contract under the SHIELD program, fueling strong bullish sentiment. The community is actively discussing the stock's ability to maintain its upward momentum against price resistance ahead of its highly anticipated earnings report, with many expecting positive developments from its server CPU demand and foundry initiatives.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to heightened global market uncertainty, fueled by renewed tariff threats against European nations and the ongoing Greenland situation. The community is sharply divided, with some anticipating a familiar "buy the dip" opportunity for the tech-heavy index, while others fear a more sustained market correction if trade tensions further escalate.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as regulatory developments create a mixed outlook: a Massachusetts judge issued a preliminary injunction against prediction market Kalshi, a move seen as highly favorable for traditional sportsbooks. This positive catalyst is juxtaposed with the NCAA's call for a federal halt on college sports betting, intensifying investor debate around regulatory impacts and the rising competition from alternative betting platforms. Community sentiment is also weighing recent analyst upgrades and an increased share buyback authorization, leading to notable stock volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed following its announcement of a record date for a digital token initiative, with many anticipating a short squeeze and other upcoming catalysts. This drives significant polarization, as some investors see substantial upside from loyalist support, while others view it as a highly speculative, politically-charged stock susceptible to market volatility and dilution. The stock remains a key talking point, reflecting the strong intersection of media, branding, and political narratives in its trading dynamics.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is captivating attention following its selection for a critical Missile Defense Agency contract vehicle, sparking renewed bullish sentiment within the quantum computing sector. While bulls anticipate further momentum from upcoming industry events like CES, community discussions remain divided between those highlighting its technological advancements and others questioning its current valuation amidst ongoing R&D.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group (TWG) is seeing significant conversation following its announced acquisition of a wine trading business valued at $125 million, to be paid in newly issued shares. This strategic expansion into luxury wine has ignited strong community debate, with investors split between concerns over the share dilution at $7.00 per share and those enthusiastically accumulating the stock on the belief of a future rebound. The intense volatility reflects the mixed sentiment surrounding this low-float entity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio...

Instil Bio Pulls Plug On Lead Drug Development

Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new questions about its pipeline and next steps.read more...

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know 

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

<a href="https://stocktwits.com/symbol/TIL">Instil Bio’s stock</a> surged over 25% on Tuesday to levels last seen in early December after Jefferies upgraded the&nbsp;shares to ‘Buy’ from ‘Hold,’ with a new price target of $52 — more than double its current level.&nbsp;The upgrade reflects Jefferies’ confidence in the potential of Instil’s lead asset, SYN-2510, a novel PD-L1xVEGF bispecific antibody targeting multiple solid tumor cancers.Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.&nbsp;A U.S. Phase 1b/2 study in non-small cell lung cancer (NSCLC) is scheduled to begin in the second half of 2025, focusing on driver gene mutation-negative non-squamous and squamous NSCLC patients.&nbsp;This trial will explore SYN-2510 in combination with chemotherapy, a promising strategy in frontline treatment settings.SYN-2510 is part of a global registrational strategy with China’s ImmuneOnco Biopharmaceuticals.&nbsp;In late 2024, ImmuneOnco started a Phase 1b/2 chemo combination study in China for frontline NSCLC. The collaboration aims to generate clinical proof-of-concept data in multiple solid tumors, with updates anticipated in early 2025.&nbsp;If successful, both companies may initiate joint randomized Phase 3 chemotherapy combination trials for NSCLC and triple-negative breast cancer (TNBC) in 2025.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TIL_sentiment_and_message_volume_Jan_7_premarket_960267c1cd.png" alt="TIL sentiment and message volume Jan 7 premarket.png" width="1318" height="324"><figcaption>TIL sentiment and message volume Jan 7 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits reacted positively, pushing sentiment to ‘extremely bullish’ and boosting its message volume.&nbsp;<stembedurl>https://stocktwits.com/Blackcoupe369/message/599159968</stembedurl>Jefferies also noted that the stock is trading at cash value, which, combined with SYN-2510’s potential, suggests substantial growth opportunities.Instil reported $122.9 million in cash reserves as of September 2024, saying it was sufficient to fund its operations through at least 2026.&nbsp;The stock has climbed over 240% in the past year, driven by optimism around its innovative cancer therapies and impending trials, making it a standout player in the small-cap oncology space.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant

Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.

Equity

Shares of Instil Bio Inc. (TIL) skyrocketed over 60% on Friday, placing it among the top five gainers on U.S. stock exchanges and one of the top 20 trending tickers on Stocktwits, where message volume jumped 340%.The surge came after Baird raised its price target on the stock to $180, implying a 146% upside, while maintaining an ‘Outperform’ rating.Baird’s optimism is growing enthusiasm for Instil’s PD-L1xVEGF bispecific antibody, driven by positive data from peers like Akeso’s ivonescimab and Summit’s BNT327 in the same space.Analysts noted recent results and data released ahead of the European Society for Medical Oncology (ESMO) meeting have increased faith in this drug class for treating cancers like triple-negative breast, RCC, and head and neck.Baird expects continued momentum in this therapeutic area at ESMO, seeing further growth opportunities for Instil Bio. Despite the recent rally, the brokerage believes the stock remains undervalued, suggesting more room for gains.Baird’s price target hike follows H.C. Wainwright’s upgrade a day earlier, when it raised its price target from $25 to $40 with a ‘Buy’ rating. Wainwright expressed increased confidence in Instil’s SYN-2510, highlighting its strong antitumor synergy compared to traditional VEGF blockers and PD-L1 antibodies.Instil also announced a restructuring plan last week, including shutting down operations in Manchester, U.K., and laying off its remaining workforce there. The restructuring will cost up to $5.5 million, including $2.2 million in asset impairments and $2 million in severance.<figure class="image"><a href="https://stocktwits.com/symbol/TIL"><img style="aspect-ratio:1320/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TIL_sentiment_and_message_volume_Sep_13_0d4fea2fed.png" alt="TIL sentiment and message volume Sep 13.png" width="1320" height="324"></a><figcaption>TIL sentiment and message volume Sep 13</figcaption></figure>Despite bullish analyst notes, retail investors remain wary. Sentiment on Stocktwits is ‘extremely bearish,’ with users questioning the sustainability of the stock’s rapid ascent.“$TIL 13$ last week, now 77$,” noted one user.<stembedurl>https://stocktwits.com/patbourque/message/585998096</stembedurl>Another warned, “$TIL from $9 to $70 in a few days!!! This is not going to go well next week.”<stembedurl>https://stocktwits.com/ProBulish/message/585995548</stembedurl>Adding to concerns, Instil’s fundamentals look shaky. The company reported zero revenue in the latest quarter, only $6.78 million in cash, and holds a $52.1 million mortgage construction loan on its Tarzana, California property, with an option to draw an additional $32.9 million.Instil Bio has soared 624% in the last month, and retail investors are exercising caution for now.Read next: <a href="https://stocktwits.com/news/markets/equity/mstr-stock-rises-on-bitcoin-buy-retail-bullish/c7z62Y5R5B">MicroStrategy Stock Surges On $1B Bitcoin Buy Amid Crypto Dip: Retail Bulls Rejoice</a> &nbsp;

Instil Bio Soars On Baird’s Price Target Boost: Retail Remains On Sidelines Amid Wild Surge

Despite a recent rally in Instil Bio shares, Baird believes the stock remains undervalued, suggesting more room for gains.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

TIL
Instil Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TIL News

TILInstil Bio Inc